Mechanisms of hormonal and antihormonal action of contraceptive progestins at the molecular level.
19-Nor synthetic progestins undergo extensive metabolism at the target cells. The resulting metabolic conversion products interact with putative steroid receptors within the cells, and through those interactions, they may exert either agonistic, synergistic and antagonistic hormonal effects. Studies conducted in our laboratories have disclosed that norethisterone (NET) and D-(1) norgestrel (LNG), two widely used contraceptive progestins, are biotransformed to several A-ring reduced (dihydro and tetrahydro) derivatives. The resulting metabolites 5 alpha-dihydro NET (5 alpha-NET) and 5 alpha-dihydro LNG bind with relative high affinity to the progesterone and androgen receptors. To gain insight into the underlying molecular events mediating the mode of action of NET and its neutral metabolites, we have examined the expression of their biological effects at target organs by using the rabbit uteroglobin gene model and the beta-glucuronidase activity of the mouse kidney. The results of a series of experiments seem to indicate that the enzyme-mediated formation of the 5 alpha (trans A/B ring junction) NET derivative results in a significant diminution of its progestational and androgenic potencies. Furthermore, 5 alpha-NET acquire a potent anti-progestational/contragestational effect as assessed in the female rabbit. These results demonstrated that 5 alpha-reduction of 19-nor progestins exerts a paradoxical effect, at least in terms of their hormone-like effects. The overall data are in line with the concept that metabolism of synthetic progestins at hormone-sensitive organs modulates their mechanisms of action.
Pérez-Palacios
G
G
Department of Reproductive Biology, National Institute of Nutrition S. Zubirán, México City, México.
Cerbón
M A
MA
Pasapera
A M
AM
Castro
J I
JI
Enríquez
J
J
Vilchis
F
F
García
G A
GA
Moralí
G
G
Lemus
A E
AE
D000818:Animals; D001667:Binding, Competitive; D001711:Biotransformation; D005260:Female; D007668:Kidney / Q000378:metabolism; D007700:Kinetics; D051379:Mice; D008807:Mice, Inbred BALB C; D009277:Nandrolone / Q000031:analogs & derivatives / Q000378:metabolism; D009640:Norethindrone / Q000378:metabolism* / Q000494:pharmacology*; D009644:Norgestrel / Q000378:metabolism* / Q000494:pharmacology*; D011282:Pregnenediones / Q000378:metabolism; D045167:Progesterone Congeners / Q000378:metabolism; D011817:Rabbits; D011944:Receptors, Androgen / Q000187:drug effects / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000187:drug effects / Q000378:metabolism*; D012741:Sexual Maturation; D013256:Steroids / Q000494:pharmacology*; D045165:Testosterone Congeners / Q000378:metabolism; D014598:Uteroglobin / Q000378:metabolism; D014599:Uterus / Q000187:drug effects / Q000378:metabolism*
D011282:Pregnenediones; D045167:Progesterone Congeners; D011944:Receptors, Androgen; D011980:Receptors, Progesterone; D013256:Steroids; D045165:Testosterone Congeners; C020175:16 alpha-ethyl-21-hydroxy-19-nor-4-pregnene-3,20-dione; D009644:Norgestrel; D009277:Nandrolone; D014598:Uteroglobin; C100075:mibolerone; D009640:Norethindrone